Genetic algorithm guided population pharmacokinetic model development for simvastatin, concurrently or non-concurrently co-administered with amlodipine

Ayyappa Chaturvedula, Mark E. Sale, Howard Lee

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

An automated model development was performed for simvastatin, co-administered with amlodipine concurrently or non-concurrently (i.e., 4 hours later) in 17 patients with coexisting hyperlipidemia and hypertension. The single objective hybrid genetic algorithm (SOHGA) was implemented in the NONMEMsoftware by defining the search space for structural, statistical and covariate models. Candidate models obtained from the SOHGA runs were further assessed for biological plausibility and the precision of parameter estimates, followed by traditional backward elimination process for model refinement. The final population pharmacokinetic model shows that the elimination rate constant for simvastatin acid, the active form by hydrolysis of its lactone prodrug (i.e., simvastatin), is only 44% in the concurrent amlodipine administration group compared with the non-concurrent group. The application of SOHGA for automated model selection, combined with traditional model selection strategies, appears to save time for model development, which also can generate new hypotheses that are biologically more plausible.

Original languageEnglish
Pages (from-to)141-149
Number of pages9
JournalJournal of Clinical Pharmacology
Volume54
Issue number2
DOIs
StatePublished - 1 Jan 2014

Keywords

  • Amlodipine
  • Drug interaction
  • Genetic algorithm
  • Population pharmacokinetics
  • Simvastatin
  • Simvastatin acid

Fingerprint Dive into the research topics of 'Genetic algorithm guided population pharmacokinetic model development for simvastatin, concurrently or non-concurrently co-administered with amlodipine'. Together they form a unique fingerprint.

  • Cite this